Beyond MRSA: VISA and VRSA: what will ward off these pathogens in health care facilities?
Todd
Betsy
B
New York-Presbyterian Hospital, Columbia University Medical Center, New York City, NY, USA. met9005@nyp.org
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D021821:Communicable Diseases, Emerging / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D003227:Conjugation, Genetic; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D004363:Drug Utilization; D006801:Humans; D017053:Infection Control / Q000458:organization & administration*; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D011159:Population Surveillance; D017410:Practice Guidelines as Topic; D011815:R Factors; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D013211:Staphylococcus aureus; D014481:United States / Q000453:epidemiology; D020713:Vancomycin Resistance
D000900:Anti-Bacterial Agents